Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Memantine add-on treatment for obsessive-compulsive disorder
IRCT20201227049851N1Phase 3Completed
- Sponsor
- Kashan University of Medical Sciences
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in obsessive compulsive disorder (OCD) comparing Memantine + sertraline with Placebo + sertraline (2 arms). Primary endpoints: Yale-Brown Obsessive Compulsive Scale total score, Yale-Brown Obsessive Compulsive Scale obsession subscale and 1 more. Started Mar 2021; status: completed.
02
Drugs
memantine
03
Conditions
obsessive compulsive disorder (OCD)
Beyond the preview
Go deeper on IRCT20201227049851N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20201227049851N1.